In this regard, we and others have demonstrated that approaches based on we and others have demonstrated that approaches based on blocking (non-activating) monoclonal antibodies (mAbs) that target CCR7 or its ligands, are highly effective in in vitro and in vivo preclinical models, including B-ALL (24), CLL (37, 40, 45), MCL (21), T-ALL (24, 25), or T-PLL (130). Here, CCR7 is linked to mantle cell lymphoma.